Apoptosis signal-regulating kinase (ASK) 1 is a mitogen-activated protein kinase kinase kinase (MAP3K) in the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase pathways that play multiple important roles in cytokine and stress responses. Here we show that ASK2, a highly related serine/threonine kinase to ASK1, also functions as a MAP3K only in a heteromeric complex with ASK1. We found that endogenous ASK2 was constitutively degraded in ASK1-deficient cells, suggesting that ASK1 is required for the stability of ASK2. ASK2 in a heteromeric complex with a kinase-negative mutant of ASK1 (ASK1-KN) effectively activated MAP2K and was more competent to respond to oxidative stress than ASK2 alone. Knockdown of ASK2 revealed that ASK2 was required for oxidative stress-induced JNK activation. These results suggest that ASK2 forms a functional MAP3K complex with ASK1, in which ASK1 supports the stability and the active configuration of ASK2. Moreover, ASK2 was found to activate ASK1 by direct phosphorylation, suggesting that ASK1 and ASK2 in a heteromeric complex facilitate their activities to each other by distinct mechanisms. Such a formation of functional heteromeric complex between different MAP3Ks may be advantageous for cells to cope with a wide variety of stimuli by fine regulation of cellular responses.
The mitogen-activated protein kinase (MAPK) 2 cascades are multifunctional intracellular signaling pathways that are evolutionarily conserved in all eukaryotic cells (1, 2) . Three main MAPK cascades that converge on extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 MAPKs have been well characterized. Each MAPK cascade consists of three classes of serine/threonine kinases, MAPK, MAPK kinase (MAP2K), and MAP2K kinase (MAP3K). MAP3K phosphorylates and thereby activates MAP2K, and activated MAP2K in turn phosphorylates and activates MAPK. A growing number of MAP3Ks have been identified, each of which activates single or multiple downstream MAPK cascades. Extensive characterization of several MAP3Ks has demonstrated that MAP3Ks are crucial to sense extracellular and intracellular stimuli and regulate cellular responses through the activation of downstream MAPK pathways (3) (4) (5) (6) (7) .
Apoptosis signal-regulating kinase (ASK) 1 is among the extensively characterized MAP3Ks (8) . ASK1 regulates the JNK and p38 MAPK pathways by directly phosphorylating and thereby activating their respective MAP2Ks, MKK4 (SEK1)/ MKK7 and MKK3/MKK6 (9, 10) . ASK1 is activated by various stresses including oxidative stress, endoplasmic reticulum stress, and calcium overload and by receptor-mediated inflammatory signals such as tumor necrosis factor and lipopolysaccharide (11) (12) (13) (14) (15) . Overexpression of ASK1 induces apoptosis in various cells through mitochondria-dependent caspase activation (11, 16, 17) . Recent analyses of ASK1-deficient mice have revealed that ASK1 is required for apoptosis induced by oxidative stress, tumor necrosis factor, and endoplasmic reticulum stress and plays essential roles in innate immune responses (12, 15, 18) .
In the present study, we showed that ASK2, a highly related kinase to ASK1, stably formed a heteromeric complex with ASK1 in mammalian cells. ASK2 was identical to MAPKKK6, which was previously reported to be a MAP3K that only weakly activated JNK but not ERK or p38 (19) . Consistent with this finding, we failed to detect apparent kinase activity of single transfection of ASK2 plasmid. Instead, we found that the effective protein expression and the kinase activity of ASK2 were facilitated by the heteromeric complex formation with ASK1. ASK2 in a complex with ASK1 was competent to respond to oxidative stress and functions as a MAP3K of the JNK and p38 MAPK pathways.
EXPERIMENTAL PROCEDURES
Cell Culture-Mouse embryonic fibroblasts (MEFs) from wild type or ASK1-deficient mice (18) and HEK293 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS), 4.5 mg/ml glucose, and 100 units/ml penicillin G in a 5% CO 2 atmosphere at 37°C. Mouse B16 melanoma cells were cultured in Dulbecco's modified Eagle's medium containing 10% FBS and 100 units/ml penicillin G in a 5% CO 2 atmosphere at 37°C. A crude population of bone marrow-derived macrophages was generated in vitro from bone marrow of wild type or ASK1-deficient mice as described with some modification (26) . Bone marrow cells were cultured in RPMI 1640 medium containing 10% heat-inactivated FBS, 100 units/ml penicillin G, 10 ng/ml of recombinant mouse granulocyte-monocyte colony stimulating factor (Strathmann Biotech), and 5 ng/ml of recombinant mouse interleukin-4 (Genzyme-Techne). The medium was replaced on day 2 and 4, and the nonadherent granulocytes and loosely adherent dendritic cells were rinsed away. On day 7 of culture, the firmly adherent cells were obtained and subjected to further analysis.
Antibodies and Reagents-Antibody to ASK2 was established as described (27) . Briefly, a GST-tagged C-terminal fragment of mouse ASK2 corresponding to amino acids 1,078 -1,292 was produced and purified from Escherichia coli strain BL21. WYK/ Izm rats were immunized via the hind footpads with the recombinant protein using Freund's complete adjuvant. The enlarged medial iliac lymph nodes from the rats were used for cell fusion with mouse myeloma cells, SP2, and the hybridoma cells were cultured in GIT medium (Wako Pure Chemicals) supplemented with 100 M hypoxanthine, 0.4 M aminopterin, 16 M thymidine, 10% FBS, and 2% BM Condimed H1 (Roche Applied Science). The antibody-secreting hybridoma was selected by screening with enzyme-linked immunosorbent assay and immunoblotting. Because of the low growth rate of the cloned hybridoma cells, the mixture of culture medium from several positive clones was used in this study. Rabbit polyclonal antibodies to ASK1 and phospho-ASK1 were described previously (11, 20) . Rabbit polyclonal antibody to ASK1 (Santa Cruz; H-300) was used in RNA interference experiments. Rat monoclonal antibody to the hemagglutinin (HA) tag (clone 3F10) was purchased from Roche Applied Science. Mouse monoclonal antibodies to FLAG (M2) and Myc (9E10) tags were purchased from Sigma and Calbiochem, respectively. Phospho-specific antibodies to JNK (Thr 183 /Tyr 185 ) and p38 (Thr 180 /Tyr 182 ) MAPK were purchased from Cell Signaling. p38 goat polyclonal antibody (C-20-G) and JNK rabbit polyclonal antibody (JNK1-FL) were purchased from Santa Cruz. Rat ␣-tubulin (YL1/2) and mouse GFP (1E4) monoclonal antibodies were purchased from Serotec and MBL, respectively. The proteasome inhibitors, MG132 and lactacystin, were purchased from Calbiochem.
Yeast Two-hybrid System-A human fibroblast WI-38 cDNA library in the prey plasmid pJG4 -5 was screened for proteins that interact with ASK1-⌬N, which lacked the N-terminal 648 amino acids, using EGY48 yeast strain containing the ␤-galactosidase reporter plasmid pSH18 -34 as described previously (11) . The bait plasmid expressing ASK1 protein was constructed in-frame with the LexA DNA-binding domain of pEG202. Plasmids of positive clones were recovered, and the cDNA inserts were sequenced. To assay the interaction between ASK1 and ASK2, the full-length mouse ASK2 cDNA was inserted in pJG4 -5. Because of the intrinsic prey-independent transcriptional activity of LexA DNA-binding domainwild type ASK1 fusion protein, the cDNA for a full-length but kinase-negative mutant of ASK1 (ASK1-KN) was inserted in pEG202. ASK1 and ASK2 constructs were co-transformed along with the reporter plasmid pSH18 -34 in EGY48 yeast strains.
Isolation of Full-length cDNAs for Human and Mouse ASK2-To clone mouse ASK2 cDNA, mouse kidney and lung cDNA libraries were screened with a partial human ASK2 cDNA fragment obtained by the two-hybrid screening as a probe, and positive clones were purified and sequenced as described previously (28) . To obtain a 5Ј cDNA fragment of mouse ASK2, rapid amplification of 5Ј cDNA ends was performed using a cDNA pool from mouse fibroblast L929 cells and a Marathon cDNA amplification kit (Clontech) according to the manufacturer's instructions. To clone human ASK2 cDNA, we designed several pairs of PCR primer based on the information including the cDNA sequences obtained by the two-hybrid screening, the deposited sequence of human MAPKKK6 (19) (GenBank TM accession number AF100318 that lacks the N-terminal sequence), the expressed sequence tag sequences encoding the N-terminal sequence (AI582755 and BF732392), and the human MAP3K6 genomic sequence. By using these primers and Pfu Turbo DNA polymerase (Stratagene), we cloned the full-length cDNA for human ASK2 by reverse transcription-PCR from total RNA isolated from HEK293 cells. The following oligonucleotides were used for the isolation of cDNAs for human and mouse ASK2: hS1, 5Ј-TCCAGATCCCAAGAT-TCCTGATCTGCCGG-3Ј; hS2, 5Ј-TCCAGAAGAACTCG-GATTGCGTTGG-3Ј; hAS1, 5Ј-ATAGGGGATCAGTGTG-TAGCTGCCAACGC-3Ј; hAS2, 5Ј-GGTTGTCGTGCAAG-TAGCCAAGTCC-3Ј; mAS1, 5Ј-TTGATGTGGAGCCCA-GCCTGCAC-3Ј; and mAS2, 5Ј-GATACGACCACACATG-CAGTACAG-3Ј.
Expression Plasmids and Adenovirus Vectors-Epitopetagged mammalian expression plasmids for ASK1 were described previously (11, 14, 20) . Kinase-negative mutants of ASK1 (ASK1-KN) in this study were constructed by replacing a lysine residue located in subdomain II of the kinase domain by arginine (K709R) or methionine (K709M). cDNAs for mouse ASK2 and its kinase-negative mutant, in which a lysine residue located in subdomain II of the kinase domain by methionine (K678M), were subcloned into pcDNA3 (Invitrogen) with N-terminal ECFP (Clontech), FLAG, or HA tags. Transfection of these expression plasmids into HEK293 cells and MEFs was performed with FuGENE 6 (Roche Applied Science) and Lipofectamine 2000 (Invitrogen), respectively, according to the manufacturer's instructions. For bacterial expression, ASK2 and ASK1 cDNAs were subcloned into pGEX-4T (GE Healthcare) with an N-terminal GST tag and pCDF-1b (Novagen) with a hexahistidine (His) tag, respectively. E. coli strain BL21 was transformed with these bacterial expression plasmids and selected on LB plates containing 50 g/ml of ampicillin and 10 g/ml of streptomycin. Recombinant adenoviruses encoding ASK1 and ␤-galactosidase were described previously (11) .
Co-immunoprecipitation Analysis-For the co-immunoprecipitation between transiently expressed proteins in HEK293 cells, the cells were lysed with the IP lysis buffer (50 mM TrisHCl, pH 8.0, 150 mM NaCl, 1% deoxycholate, 1% Triton X-100, 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and 5 g/ml aprotinin). The cell extracts were clarified by centrifugation, and the supernatants were immunoprecipitated with FLAG antibody gel (M2 gel, Sigma). The beads were washed three times with the IP lysis buffer before analysis by SDS-PAGE. For the endogenous interaction between ASK1 and ASK2, MEFs were lysed in the IP lysis buffer. The supernatants obtained by centrifugation of the cell extracts were incubated with either ASK1 rabbit polyclonal antibody or control normal rabbit IgG (Santa Cruz) for overnight at 4°C. After the 1-h incubation with protein A-Sepharose beads (GE Healthcare), the beads were washed three times with the IP lysis buffer and subjected to SDS-PAGE.
Immunoblotting Analysis-Cell extracts and immunoprecipitates were resolved on SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes. After blocking with 5% skim milk in TBS-T (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween 20), the membranes were probed with antibodies. The antibody⅐antigen complexes were detected using the ECL system (GE Healthcare).
Quantitative PCR Analysis-Total RNA was isolated from MEFs using Isogen (Wako) and reverse transcribed with SuperScript II reverse transcriptase (Invitrogen). Primers were designed using Primer Express 2.0 software (Applied Biosystems). The following oligonucleotides were used: ASK1 sense, 5Ј-CCCTGGAGACCCTGCATTT-3Ј; ASK1 antisense, 5Ј-CA-TCTCCACCACAGCAATATCTG-3Ј; ASK2 sense, 5Ј-TGGC-ACAGCCTTCCTTGTTC-3Ј; ASK2 antisense, 5Ј-CACAATC-CGAGTTCTTCTGGAAA-3Ј; glyceraldehyde-3-phosphate dehydrogenase sense, 5Ј-TGTGTCCGTCGTGGATCTGA-3Ј; and glyceraldehyde-3-phosphate dehydrogenase antisense, 5Ј-CCTGCTTCACCACCTTCTTGA-3Ј. Quantitative reverse transcription-PCR was carried out by ABI PRISM 7000 sequence detection system using SYBR Green PCR Master Mix (Applied Biosystems). A standard curve of critical threshold versus log concentration for each transcript was generated by serial dilutions of cDNA pool from wild type (WT) MEFs. Each transcript level in WT and ASK1-deficiend MEFs was calculated using ABI PRISM 7000 SDS software, and the relative mRNA expression of ASK1 or ASK2 in WT versus ASK1 deficient MEFs was determined by normalization to glyceraldehyde-3-phosphate dehydrogenase expression.
In Vitro Kinase Assay-GST-MKK6 and GST-p38-KN, were prepared as described previously (11). FLAG-ASK1 or -ASK2 was immunoprecipitated from HEK293 cells as described under "Co-immunoprecipitation Analysis." The immune complex was incubated in a kinase buffer containing 50 mM TrisHCl, pH 8.0, 20 mM MgCl 2 , 1 mM dithiothreitol, and 100 M ATP together with GST-MKK6 for 10 min at room temperature. The kinase reaction was then added with GST-p38-KN and incubated for further 10 min at room temperature. The samples were subjected to SDS-PAGE followed by immunoblotting using phospho-p38 antibody.
Measurement of Caspase-3-like Activity-Caspase-3-like activity in cell extracts was measured by a CPP32/caspase-3 fluorometric protease assay kit (MBL) following the manufacturer's instructions, in which a fluorogenic synthetic peptide DEVD-7-amino-4-trifluoromethyl coumarin was used as a substrate. The fluorescence of the released 7-amino-4-trifluoromethyl coumarin was measured with an excitation wavelength of 360 nm and an emission wavelength of 530 nm using Twinkle LB970 (Berthold).
RNA Interference-Small interference RNAs (siRNAs) for mouse ASK1 and ASK2 were purchased from Invitrogen (Stealth Select RNAi, MSS218536 and MSS225396, respectively). Stealth RNAi Negative CTL (Invitrogen) was used as a control. B16 cells that were seeded in 12-well plates were transfected with 40 pmol/well of siRNA using 2 l/well of Lipofectamine RNAiMAX (Invitrogen). After 30 h, the cells were treated or untreated with 0.5 mM H 2 O 2 for 30 min and were subjected to immunoblotting analysis.
RESULTS

Identification of ASK2 as an ASK1-binding Protein-To iden-
tify molecules that interact with ASK1, we employed the yeast two-hybrid system using a deletion mutant of ASK1 (ASK1-⌬N) that lacked N-terminal 648 amino acids as a bait. In a screen of human fibroblast WI-38 cDNA library, we identified a positive clone that encodes a putative serine/threonine kinase. Subsequent cloning of corresponding human and mouse fulllength cDNAs revealed that this kinase was closely related to ASK1 and therefore was designated as ASK2 (also called MAP-KKK6 (19)) (Fig. 1, A and B) . Human and mouse ASK2 consist of 1,288 and 1,291 amino acids, respectively, and each possessed a kinase domain in the middle part of the molecule with long N-and C-terminal flanking regions. Overall structure of ASK2 was well conserved with that of ASK1 (Fig. 1A) . The interaction of ASK1 with the cloned full-length version of mouse ASK2 was confirmed by the yeast two-hybrid assay (Fig.  1C) . We also detected the interaction between Myc-tagged ASK1 (Myc-ASK1) and FLAG-tagged ASK2 (FLAG-ASK2) by co-immunoprecipitation analysis in HEK293 cells (Fig. 1D) .
To examine the endogenous interaction of ASK1 and ASK2, we established an antibody that specifically recognizes ASK2. The ASK2 antibody selectively recognized ASK2 but not ASK1 that were transiently expressed in HEK293 cells (Fig. 1E) . Cell lysates from MEFs were subjected to immunoprecipitation with the ASK1 antibody, and endogenous ASK2 co-purified with ASK1 was clearly detected by immunoblotting with the ASK2 antibody (Fig. 1F ). This result suggested that ASK2 forms a heteromeric complex with ASK1 in unstimulated cells. A, ClustalW alignment of the amino acid sequences of human ASK2, mouse ASK2, and human ASK1 (hASK2, mASK2, and hASK1, respectively). Residues that are identical between two of the three proteins and among all three proteins are shaded in gray and black, respectively. The kinase domain is underlined. The threonine residue that is highlighted in Fig. 4A is indicated by a red arrowhead. The hASK2 cDNA fragment corresponding to amino acids (aa) 757-1,288 (aa 757 in hASK2 is indicated by a blue arrowhead) was obtained by the two-hybrid screening. The 5Ј fragment of hASK2 corresponding to aa 1-756 was cloned by reverse transcription-PCR using the primers indicated as blue arrows. The mASK2 cDNA fragments corresponding to aa 349 -1,291 (aa 349 in mASK2 is indicated by a green arrowhead) and aa 1-348 were obtained by the cDNA library screening and the 5Ј-rapid amplification of cDNA ends, respectively. The primers used in the 5Ј-rapid amplification of cDNA ends are indicated as green arrows. Respective nucleotide sequences of the PCR primers are shown under "Experimental Procedures. " B, a phylogenetic tree of the human MAP3K family. A phylogenetic tree was created by the alignment of kinase domains of the human MAP3K molecules using the ClustalW program of the Lasergene Megaline software. The scale under the tree indicates the distance sequences in substitution event units. C, interaction of ASK2 with ASK1 in yeast. The bait plasmid encoding a kinase-negative mutant of ASK1 (ASK1-KN) fused to the DNA-binding domain and/or the prey plasmid encoding ASK2 fused to the transcriptional activation domain were co-transformed along with the ␤-galactosidase reporter plasmid pSH18 -34 in EGY188 yeast strains. Three independent clones of each transformant were streaked onto control (dextrose) and indicator (glucose) plates. D, interaction of ASK2 with ASK1 in mammalian cells. HEK293 cells were transiently co-transfected with Myc-tagged ASK1 (Myc-ASK1) and/or FLAG-tagged ASK2 (FLAG-ASK2). The cell lysates were immunoprecipitated with FLAG antibody (IP: Flag), and coimmunoprecipitated ASK1 with ASK2 was detected by immunoblotting (IB) with Myc antibody (top panel). The immunoprecipitated FLAG-ASK2 and the expression level of Myc-ASK1 were confirmed by IB with FLAG and Myc antibodies, respectively (lower two panels). E, establishment of the ASK2 antibody. HEK293 cells were transiently expressed with either FLAG-ASK1 or FLAG-ASK2. Cell lysates were subjected to IB with ASK2 (upper panel) and FLAG (lower panel) antibodies. F, endogenous interaction between ASK1 and ASK2. Cell lysates from MEFs were immunoprecipitated with ASK1 antibody (IP: ASK1) or control rabbit IgG (IP: IgG). Co-immunoprecipitated ASK2 with ASK1 was detected by IB with ASK2 antibody (top panel). The immunoprecipitated ASK1 and the amount of ASK2 in cell lysate for each immunoprecipitation were confirmed by IB with ASK1 and ASK2 antibodies, respectively (lower two panels).
ASK1 Stabilizes ASK2-By using the ASK2 antibody, we noticed by chance that expression of ASK2 was strongly reduced in ASK1-deficient cells including MEFs and bone marrow-derived macrophages ( Fig. 2A) . Expression of ASK2 mRNA was not decreased (even increased) in ASK1-deficient (Ϫ/Ϫ) MEFs as compared with wild type (ϩ/ϩ) cells (Fig. 2B) , suggesting that reduction of synthesis or augmentation of degradation of ASK2 proteins may occur in ASK1-deficient cells. When we treated ASK1-deficient MEFs with either Lactacystin or MG132 (both are the proteasome inhibitors), an expression of endogenous ASK2 comparable with that in wild type MEFs was observed (Fig. 2C) . On the other hand, the treatment of wild type MEFs with these reagents had little effect on the expression of ASK2. These results suggested that ASK2 is constitutively degraded through the ubiquitin-proteasome system in the absence of ASK1.
To confirm that degradation of ASK2 in ASK1-deficient cells was caused by the deficiency of ASK1, we reintroduced ASK1 into ASK1-deficient MEFs using adenovirus vectors and examined the expression of endogenous ASK2. As shown in Fig. 2D (middle panels), endogenous ASK2 expression in ASK1-deficient cells (Ϫ/Ϫ) was rescued by the exogenous ASK1 expressed using relatively low doses (multiplicity of infection of 5-20) of adenovirus encoding HA-ASK1 (Ad-HA-ASK1) in a dose-dependent manner. On the other hand, ASK2 expression was not increased by the expression of exogenous ASK1 in wild type (ϩ/ϩ) cells (Fig.  2D, left panels) , precluding the possibility that ASK2 antibody crossreacted with exogenously expressed ASK1 in ASK1-deficient cells. This result also suggested that the amount of endogenous ASK1 is sufficient for the maximal expression of endogenous ASK2 in wild type MEFs. Consistently, endogenous ASK2 expression was saturated by the expression of much larger amounts of ASK1 accomplished by the infection with higher doses (multiplicity of infection of 50 -200) of Ad-HA-ASK1 in ASK1-deficient cells (Fig. 2D, right panels) . These results clearly demonstrated that degradation of endogenous ASK2 was prevented in the presence of ASK1. Interestingly, exogenous expression of a kinase-negative mutant of ASK1 (ASK1-KN) instead of wild type ASK1 sufficiently suppressed the ASK2 degradation (Fig.  2E) , indicating that ASK1-dependent stabilization of ASK2 does not require the kinase activity of ASK1.
C-terminal Region of ASK1 Binds to ASK2 and Inhibits the Degradation of ASK2-The above data
showing the kinase-independent activity of ASK1 to suppress ASK2 degradation suggested that ASK2 stability is simply supported by the physical interaction with ASK1. Because the coiled-coil domain in the C-terminal region of ASK1 (ASK1-CT) has been shown to be required for homo-oligomerization of ASK1 (20, 21), we examined whether ASK1-CT is also required for the association of ASK1 with ASK2 by using HAtagged deletion mutants of ASK1 as shown in Fig. 3A . HA-ASK1-CT but not HA-ASK1-⌬C was found to be co-precipitated with FLAG-ASK2, indicating that ASK1-CT was necessary and sufficient for the binding of ASK1 to ASK2 (Fig. 3B) .
We therefore examined whether ASK1-CT is also involved in the suppression of ASK2 degradation. Transfection of plasmids encoding ASK1-⌬C into ASK1-deficient MEFs failed to rescue the expression of ASK2 (Fig. 3C) , suggesting that ASK1-CT is necessary not only for the association with ASK2 but also for the suppression of ASK2 degradation. Expression of ASK1-CT in ASK1-deficient MEFs rescued endogenous ASK2 expression in a manner dependent on the expression levels of ASK1-CT (Fig. 3C) , although ASK1-CT was less effective to suppress ASK2 degradation than ASK1-WT, possibly because of the FIGURE 2. ASK1 stabilizes ASK2. A, expression of ASK2 is reduced in MEFs and bone marrow-derived macrophages (BMDM) derived from ASK1-deficient mice. Cell lysates were obtained from independent two preparations of MEFs (MEF #1 and #2) and bone marrow-derived macrophages, each from WT (ϩ/ϩ) and ASK1-deficient (Ϫ/Ϫ) mice, and were subjected to IB with ASK2 antibody (upper panels). IB with p38 antibody was used for a loading control (lower panels). B, expression of ASK2 mRNA is not reduced in ASK1-deficient cells. insufficient conformation of ASK1-CT for a full rescue of ASK2 expression. These results suggested that ASK1, mainly through its C-terminal region, binds to ASK2 and support the effective protein expression of ASK2 by preventing its constitutive degradation.
Co-expression with ASK1 Confers Basal Kinase Activity to ASK2-We next sought to determine the activation state of ASK2 when it is stabilized in a heteromeric complex with ASK1. We have previously found that activation of ASK1 is tightly regulated by the phosphorylation of a threonine residue within the activation loop of ASK1 (Thr 838 and Thr 845 of human and mouse ASK1, respectively) and that the phospho-specific antibody, which recognizes the phosphorylation of this threonine residue, monitors the activation state of ASK1 (20) . Comparison of amino acid sequences between ASK1 and ASK2 revealed that all amino acids but one in the activation loops of ASK1 and ASK2 were identical (Fig. 4A) . This close similarity of the primary structure between the two kinases suggested that the kinase activity of ASK2 is also regulated by phosphorylation of the corresponding threonine residue in ASK2 to Thr 838 in human ASK1 (Thr 806 and Thr 807 of human and mouse ASK2, respectively).
We first examined the phosphorylation state of ASK2 in bacterial cells to negate the constitutive degradation of ASK2 when it was singly expressed in mammalian cells (Fig. 4B) . GSTtagged ASK2 (GST-ASK2) co-expressed with hexahistidinetagged kinase-negative ASK1 (His-ASK1-KN), but not singly expressed GST-ASK2, was recognized by the phospho-ASK antibody, indicating that the phosphorylation at Thr 807 of ASK2 was induced by the presence of ASK1 (Fig. 4B, first and  second lanes) . On the other hand, a kinase-negative mutant of ASK2 (ASK2-KN) was not reactive to the antibody even when it was co-expressed with ASK1-KN (Fig. 4B, third and fourth lanes) . These results suggested that the induction of ASK2 phosphorylation in the presence of ASK1 is the consequence of autophosphorylation of ASK2. ASK1 thus appears to not only support the effective protein expression but also confer the kinase activity to ASK2. These results also suggested that the kinase activity of ASK1 is not required for the induction of autophosphorylation of ASK2 as is the case with the suppression of ASK2 degradation by ASK1 (Fig. 2E) . ASK1 may thus allosterically modulate but not directly phosphorylate ASK2 to induce the kinase activity of ASK2.
Suppression of ASK2 Degradation Is Insufficient for the Maintenance of ASK2 Activity by ASK1-Because ASK1-CT inhibited ASK2 degradation (Fig. 3C) , we examined whether the kinase activity of ASK2 stabilized by ASK1-CT was equivalent to that of ASK2 co-expressed with full-length ASK1. When GST-ASK2 was co-expressed with His-ASK1-CT in bacterial cells, ASK2 activity, which was detected by the phospho-ASK antibody, was much lower than GST-ASK2 co-expressed with full-length His-ASK1-KN (Fig.  4C) . Also in mammalian cells, ASK2 activity was observed by co-expression with full-length ASK1-KN but not with ASK1-CT (Fig. 4D, left panels) , although both ASK1 mutants bound almost equivalently to ASK2 (right panels). These results suggested that ASK1-CT inhibits ASK2 degradation but is insufficient for the maintenance of ASK2 activity. This implies that the two actions of ASK1 on ASK2, namely the stabilization and the support of kinase activity, may be regulated by distinct mechanisms. The former appears to rely on the association of ASK1 with ASK2, mainly through the C-terminal region of ASK1, whereas the latter appears to require the additional region of ASK1 other than the C-terminal region to support the active configuration of ASK2.
Co-expression with ASK1 Confers Oxidative Stress Responsiveness to ASK2-We hypothesized that ASK2 in a physiological heteromeric complex with ASK1 might be competent for stimulation-induced activation. To examine this possibility, we compared the responses of ASK2 alone and ASK2 co-expressed with ASK1 to H 2 O 2 in HEK293 cells (Fig. 4E) . To distinguish the sizes of ASK1 and ASK2 on SDS-PAGE, ASK1 with a relatively large tag (FKP3) in its N-terminal was used in this experiment. Phosphorylation of ASK2 at Thr 807 was found to increase in response to H 2 O 2 in the cells co-expressing ASK2 and ASK1-KN (Fig. 4E, third and fourth lanes) , whereas singly expressed ASK2 did not respond to H 2 O 2 (Fig. 4E, first and  second lanes) . ASK2-KN co-expressed with ASK1-KN was not phosphorylated at Thr 807 irrespective of the H 2 O 2 treatment ( Fig. 4E, fifth and sixth lanes) . These results suggested that ASK2 forms a functional complex with ASK1, in which ASK2 is activated in response to oxidative stress such as H 2 O 2 . ASK2 in a Complex with ASK1 Functions as a MAP3K-We next examined whether ASK2 functions as a MAP3K. To evaluate the MAP2K activating ability of ASK2, FLAG-ASK2 immunoprecipitated from HEK293 cells was subjected to an immune complex kinase assay using GST-MKK6 and GSTp38-KN as sequential in vitro substrates (Fig. 5A) . Only when MKK6 is activated by MAP3K, is activating phosphorylation of GST-p38-KN detected by phospho-p38 antibody. Although FLAG-ASK2 alone showed no apparent MAP2K activating ability (Fig. 5A, second lane) , FLAG-ASK2-WT but not FLAG-ASK2-KN co-immunoprecipitated with Myc-ASK1-KN effectively activated MKK6 (third and fifth lanes) to a similar extent to that activated by FLAG-ASK1 (first lane). ASK2-WT in a complex with ASK1-KN also activated MKK4 (SEK1) in vitro in a similar experiment (data not shown). These results demonstrated that ASK2 in a heteromeric complex with ASK1 directly phosphorylated and activated MAP2K in vitro. The ASK1-dependent MAP3K activity of ASK2 was also observed in vivo; activation of endogenous JNK and p38 but not ERK was induced by the co-expression of ASK2-WT with ASK1-KN in HEK293 cells (Fig. 5B, sixth lane,  and data not shown) .
One of the consequences of strong activation of JNK and p38 pathways appears to be the induction of apoptosis. Indeed, overexpression of ASK1 has been shown to induce apoptosis in various cell types (11, 16, 17) . We therefore examined the apoptosis-inducing activity of ASK2 by measuring the caspase-3-like activity in ASK2-expressing HEK293 cells. ASK2-WT was sufficiently expressed by the coexpression with ASK1-CT but only marginally induced JNK and caspase-3-like activities (Fig. 5C ). This was consistent with the above data that ASK1-CT inhibited ASK2 degradation but was insufficient for the maintenance of ASK2 activity (Figs. 3C and 4D ). On the other hand, ASK2-WT but not -KN, only when co-expressed with ASK1-KN, strongly induced caspase-3-like activity concomitant with strong JNK activation (Fig. 5C ), suggesting that ASK2 possesses kinasedependent apoptosis-inducing activity in the presence of ASK1.
To assess the physiological function of ASK2 as a MAP3K, we examined the requirement of ASK2 for JNK activation in mouse B16 melanoma cells, which were found to express substantial amounts of both ASK1 and ASK2 (Fig. 5D) . Transfection of siRNA for ASK1 into these cells reduced expression of not only ASK1 but also ASK2 when compared with control siRNA-transfected cells, indicating that expression of ASK2 depended on ASK1 also in these cells. In ASK2 knockdown cells, H 2 O 2 -induced activation of JNK was impaired as well as in ASK1 knockdown cells, although expression of ASK1 was not decreased (even increased). These results suggested that ASK2 is required for oxidative stress-induced activation of JNK.
ASK2 Activates ASK1 by Phosphorylation-Because ASK1, irrespectively of its kinase activity, supported kinase activity of ASK2, there was a possibility that ASK2 reciprocally supported ASK1 activity in the same manner. When ASK1-WT and/or ASK2-KN were expressed in HEK293 cells, however, phosphorylation of Thr 838 of ASK1 was not increased but inhibited in the presence of ASK2-KN (Fig. 6A) , excluding this possibility. Instead, we found that the phosphorylation level of Thr 838 of His-ASK1-KN co-expressed with GST-ASK2-WT was higher than that with GST-ASK2-KN in bacterial cells (Fig. 4B) . Moreover, robust phosphorylation of ASK1-KN was induced by coexpression with ASK2-WT in HEK293 cells (Fig. 6B) . These results suggested that ASK2 activates ASK1 by direct phosphorylation of Thr 838 of ASK1. Taken together with the fact that ASK1 supports ASK2 activity, these results also suggested that ASK1 and ASK2 activate each other in the heteromeric complex. To evaluate this possibility, we examined the activation states of ASK1-WT and ASK2-WT when either or both of these were expressed using adenovirus vectors in MEFs (Fig. 6C) . Phosphorylation levels of ASK1 and ASK2 were much higher in co-expressed cells than in cells expressing either ASK1 or ASK2. These results suggested that ASK1 and ASK2 in a heteromeric complex facilitate their activities to each other by distinct mechanisms.
DISCUSSION
Recently biological significance of heteromeric complex formation between different MAP3Ks has received a great deal of attention. B-Raf and Raf-1, Ras-activated MAP3Ks that regulate the ERK pathway, have been shown to form a complex in which B-Raf trans-activates Raf-1 (22) . Several oncogenic mutants of B-Raf possess reduced kinase activity toward MAP2K but instead exhibit constitutive transactivating activity toward Raf-1, resulting in the robust activation of the ERK pathway (22) . Another MAP3K, mixed lineage kinase 3, has recently been identified as a novel component of the B-Raf⅐Raf-1 complex and is required to maintain the integrity of the complex (23). ASK1 has also been shown to associate with other MAP3Ks, TAK1 and Raf-1 (24, 25) . By the complex formation with respective kinases, ASK1 inhibits the TAK1-NF-B pathway, and the kinase activity of ASK1 is inhibited by Raf-1. Taken together with the novel ASK1⅐ASK2 complex presented here, formation of a heteromeric complex between different MAP3Ks may be a crucial mechanism, by which the limited number of MAP3Ks elicits the highly divergent biological activities.
In this study, we showed that ASK2 stably forms a heteromeric complex with ASK1, in which the effective protein expression of ASK2 was supported by ASK1 (Fig. 7A) . This ASK1-dependent expression system of ASK2 appears to contribute to the preferential production of ASK1-ASK2 heteromeric rather than ASK2 homomeric complexes. The heteromeric complex with ASK1 may be a suitable platform for ASK2 to exert its activity in stress responses. Indeed, we found that ASK2 in a complex with ASK1 was competent to respond to oxidative stress and functions as a MAP3K of the JNK and p38 MAPK pathways. Interestingly, ASK1 but not ASK2 binds thioredoxin, which is a potent endogenous inhibitor of ASK1 (11) . 3 The ASK1⅐ASK2 heteromeric complex may thus confer to ASK2 not only stability and kinase activity but also regulatory mechanisms by oxidative stress.
In the heteromeric complex, we also found that ASK2 activated ASK1 by direct phosphorylation of Thr 838 of ASK1. We thus propose that ASK1 and ASK2 facilitate each other's activity by distinct mechanisms, namely, phosphorylation-independent activation of ASK2 by ASK1 and phosphorylationdependent activation of ASK1 by ASK2 (Fig. 7B) . Whereas the former mechanism is indispensable for ASK2 activation, the latter may be dispensable for ASK1 activation in a physiological setting in which ASK2 expression is lacking or limited. In such a setting, ASK1 homomeric complexes may dominantly operate, because ASK1 expression appears not to depend on ASK2 as demonstrated by the experiment of ASK2 knockdown (Fig.  5D) . Therefore, tissue distribution and transcriptional regulation of ASK2 would be informative to elucidate the physiological relevance of phosphorylation-dependent regulation by ASK2 to the activation and function of ASK1.
Recently, we have found that endogenous ASK1 constitutively forms a high molecular mass complex, which we designate ASK1 signalosome (21) . Our present data imply that ASK2 is a novel component of the ASK1 signalosome in which ASK2 may modulate the capacity and sensitivity of the signalosome for various stresses and elicit appropriate cellular responses. FIGURE 7 . Models for the roles of ASK2 in the ASK1⅐ASK2 heteromeric complex. A, a model for the regulation of ASK2 activity in the complex with ASK1. ASK1 binds to ASK2 and support the effective protein expression of ASK2 by preventing its constitutive degradation. Consequently, ASK1 and ASK2 form a stable heteromeric complex, in which ASK2 may be allosterically modulated by ASK1 and gains basal activity as a functional MAP3K. B, a model for the mutual regulation of ASK1 and ASK2 in the heteromeric complex. ASK1 and ASK2 facilitate each other's activity by distinct mechanisms, namely, phosphorylation-independent activation of ASK2 by ASK1 and phosphorylation-dependent activation of ASK1 by ASK2.
